Bipolar Disorder

Top Story

Otsuka, Lundbeck initiate phase 3 trials of Rexulti for bipolar I disorder

October 16, 2017

Otsuka Pharmaceutical Co. and Lundbeck recently announced initiation of patient enrollment for two global phase 3 clinical trials of Rexulti for treatment of manic episodes associated with bipolar I disorder.

The FDA approved Rexulti (brexpiprazole) in July 2015 for treatment of schizophrenia and as an adjunctive treatment for major depressive disorder.

In the Journals

Study reveals potential drug target for bipolar disorder, schizophrenia

October 11, 2017
Recent findings suggested dopamine synthesis capacity as a potential drug target for bipolar disorder and schizophrenia. “The dopamine hypothesis suggests that…
In the Journals

Midday bright light therapy improves bipolar depression

October 9, 2017
Adjunctive bright light therapy at midday improved remission rate and depression symptoms among adults with bipolar I or II disorder and depression. “We…
FDA News

FDA approves new dosage of Ingrezza for tardive dyskinesia

October 6, 2017
The FDA has approved an 80-mg capsule of Ingrezza for treatment of tardive dyskinesia in adults, according to a manufacturer-issued press release. Ingrezza (valbenazine…
More Headlines »
CME

Familiality and Indicators of Risk for Bipolar Disorder in Youth with Attention-Deficit/Hyperactivity Disorder

Psychiatric Annals, September 2014, Volume 44 Issue 9
Our literature review aims to identify risks for pediatric bipolar disorder in youth in the presence of symptoms of…
More »
CME

Pediatric Internalizing Disorders: October 2017

AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals

More »
Resource Centers
Psych Congress

Psych Congress

Video
Meeting News

VIDEO: Genetic predictors of tardive dyskinesia

May 20, 2017
More »
Advertisement
Advertisement